What is BEXXAR? ^1,³

BEXXAR is composed of the monoclonal antibody Tositumomab and the radioisotope Iodine-131 attached to the monoclonal antibody Tositumomab.

Radiation uses high-energy particle beams and/or rays that may destroy cancer cells and normal cells. There are different kinds of radiation. External radiation is given by special machines outside your body that point radiation beams at the tumor. BEXXAR is comprised of two components: (1) a monoclonal antibody and (2) a monoclonal antibody with a radioisotope attached. This substance is injected into the body through a vein (intravenous), and emits radiation internally.

Has BEXXAR helped patients like me?¹

BEXXAR is for patients with CD20-positive, low-grade, follicular non-Hodgkin’s lymphoma. BEXXAR is approved by the FDA for patients who have already received either chemotherapy or Rituxan, or a combination of both, and whose disease has not responded to previous therapy or has returned. BEXXAR is also for patients with transformed disease.

Since everyone is different, no one can say for sure whether BEXXAR will fight your disease, or for how long. BEXXAR has been studied for over 13 years. Five studies included patients from several different treatment centers who had low-grade, follicular, or transformed lymphoma, whose lymphoma had returned after receiving several other treatments. After treatment with BEXXAR, about half of these patients showed a response. For example, their tumors had shrunk to at least half the size they were before treatment with BEXXAR, or the tumors had gone away completely and could no longer be felt by a doctor or seen on a scan.

Is there anything I need to know before getting BEXXAR?¹

If you and your doctor decide that BEXXAR is right for you, there’s some Important Safety Information you should know before starting treatment. Click here for Important Safety Information about BEXXAR.

WARNINGS ¹

Treatment with BEXXAR does involve risk.

Serious Allergic Reaction: Patients may develop serious allergic reactions with the intravenous (IV) infusion of BEXXAR. In some cases, death has been reported. Medications for the treatment of severe reactions should be available for immediate use by a physician. Patients who develop severe reactions should have the infusion of BEXXAR stopped and receive appropriate medical attention.

Low Blood Counts: Most patients who received BEXXAR developed prolonged and severe low blood counts. This can lead to serious infections or bleeding problems.

Not for Pregnant Women: BEXXAR can harm a fetus when given to a pregnant woman.

Special Requirements: BEXXAR contains radioactive material and should be administered only by physicians and other healthcare workers who are qualified by training in the safe use and handling of radioactive materials.

Click here for Important Safety Information about BEXXAR

Complete Prescribing Information for
BEXXAR (Tositumomab and Iodine I 131 Tositumomab)

[ RETURN TO TOP ]

What is BEXXAR? 1,3

What is BEXXAR? ^1,³